Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 3/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25272538 | 1.00 | CCNE2 (0.35) | CCNE2CCNE1CDK2MKNK1CHRM1 | |
| SCHEMBL25238078 | 0.86 | CNR1 (0.35) | CCNE2CCNE1CDK2CHRM1CNR1 | |
| SCHEMBL25231123 | 0.83 | ALDH1A1 (0.35) | CCNE2CCNE1CDK2CHRM1 | |
| SCHEMBL25231135 | 0.81 | PDE1B (0.35) | CTSSCTSKPDE1B | |
| SCHEMBL25281941 | 0.79 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL25678121 | 0.79 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL25281942 | 0.79 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL3018031 | 0.71 | ROCK2 (0.44) | — | |
| SCHEMBL12013167 | 0.70 | LMNA (0.44) | — | |
| SCHEMBL2359901 | 0.70 | EGFR (0.36) | CCNE1CDK2CTSSCTSKPDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473290-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL MYERS-SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| EP-3935058-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, JAK3, IFNAR1 | CCNE2 3489/4885CCNE1 4099/4885CDK2 632/4885 |
| US-12473290-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | TYK2, JAK3, IFNAR1 | CCNE2 3489/4885CCNE1 4099/4885CDK2 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.